Bullfrog AI Holdings, Inc. Common Stock

Healthcare US BFRG

1.7377USD
-0.0323(1.82%)

Last update at 2025-06-13T16:46:00Z

Day Range

1.701.78
LowHigh

52 Week Range

1.438.35
LowHigh

Fundamentals

  • Previous Close 1.77
  • Market Cap18.47M
  • Volume92529
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.28587M
  • Revenue TTM0.07M
  • Revenue Per Share TTM0.009
  • Gross Profit TTM 0.06M
  • Diluted EPS TTM-0.84

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -2.80249M -0.58584M -0.34169M
Minority interest - - -
Net income -2.80249M -0.58584M -0.34169M
Selling general administrative 1.86M 0.56M 0.35M
Selling and marketing expenses - - -
Gross profit 0.00920M 0.00000M 0.00000M
Reconciled depreciation 0.00104M - -
Ebit -2.45534M -0.55536M -0.34719M
Ebitda -2.45430M -0.55536M -0.34719M
Depreciation and amortization 0.00104M - -
Non operating income net other - - -
Operating income -2.45580M -0.55536M -0.34719M
Other operating expenses 2.47M 0.56M 0.35M
Interest expense 0.35M 0.04M 0.01M
Tax provision - - -
Interest income - - -
Net interest income -0.34714M -0.04040M -0.01177M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 0.35M - -
Total revenue 0.01000M 0.00000M 0.00000M
Total operating expenses 2.47M 0.56M 0.35M
Cost of revenue 0.00080M 0.00000M 0.00000M
Total other income expense net 0.00046M 0.00992M 0.02M
Discontinued operations - - -
Net income from continuing ops -2.80249M -0.58584M -0.34169M
Net income applicable to common shares - -0.58584M -0.34169M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 2.78M 0.08M 0.01M 0.00502M
Intangible assets - - - -
Earning assets - - - -
Other current assets 0.15M - - -
Total liab 0.18M 3.14M 1.02M 0.55M
Total stockholder equity 2.59M -3.05735M -1.00911M -0.54052M
Deferred long term liab - - - -
Other current liab 0.08M 1.97M 0.71M 0.24M
Common stock 0.00006M 0.00004M 0.00027M 0.00025M
Capital stock 0.00006M 0.00004M 0.00027M 0.00025M
Retained earnings -9.75492M -4.39905M -1.59657M -1.01073M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 2.62M 0.06M 0.01M 0.00502M
Cash and equivalents - - - -
Total current liabilities 0.18M 3.14M 1.02M 0.55M
Current deferred revenue - 0.03M 0.01000M -
Net debt -2.62473M 1.52M 0.58M 0.20M
Short term debt - 1.58M 0.59M 0.21M
Short long term debt - 1.58M 0.59M 0.21M
Short long term debt total - 1.58M 0.59M 0.21M
Other stockholder equity 12.35M 1.34M 0.59M 0.47M
Property plant equipment - - - -
Total current assets 2.77M 0.07M 0.01M 0.00502M
Long term investments - - - -
Net tangible assets - - -1.00911M -0.54052M
Short term investments - - - -
Net receivables - - - -
Long term debt - - - -
Inventory - - - -
Accounts payable 0.10M 0.54M 0.07M 0.09M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.00000M - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.00000M - - -
Deferred long term asset charges - - - -
Non current assets total 0.00597M 0.00770M 0.00000M 0.00000M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -0.00874M - -
Change to liabilities - -0.01585M 0.06M
Total cashflows from investing activities - - -
Net borrowings - 0.39M 0.21M
Total cash from financing activities 0.97M 0.39M 0.21M
Change to operating activities - 0.11M 0.11M
Net income -2.80249M -0.58584M -0.34169M
Change in cash 0.05M 0.00500M -0.00177M
Begin period cash flow 0.01M 0.00502M 0.00679M
End period cash flow 0.06M 0.01M 0.00502M
Total cash from operating activities -0.91089M -0.38240M -0.21171M
Issuance of capital stock - - -
Depreciation 0.00104M - -
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -
Other cashflows from financing activities 1.02M 0.39M 0.21M
Change to netincome - 0.09M 0.07M
Capital expenditures 0.00874M 0.00000M 0.00000M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 1.14M 0.10M 0.06M
Stock based compensation 0.34M 0.10M 0.09M
Other non cash items 0.41M 0.00729M -0.01727M
Free cash flow -0.91963M -0.38240M -0.21171M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BFRG
Bullfrog AI Holdings, Inc. Common Stock
-0.0323 1.82% 1.74 - - 284.18 4.83 205.12 -12.0243
GEHC
GE HealthCare Technologies Inc.
-0.525 0.72% 72.58 22.91 20.12 2.01 5.52 2.39 13.30
VEEV
Veeva Systems Inc Class A
3.35 1.19% 285.50 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc
- -% 13.65 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc
-0.15 2.12% 6.92 31.84 26.25 0.05 4.60 0.04 0.12

Reports Covered

Stock Research & News

Profile

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Bullfrog AI Holdings, Inc. Common Stock

325 Ellington Boulevard, Gaithersburg, MD, United States, 20878

Key Executives

Name Title Year Born
Mr. Vininder Singh Founder, Chairman & CEO 1970
Mr. Dane R. Saglio Chief Financial Officer 1958
Mr. J. T. Koffenberger Chief Information Officer NA
Hon. Thomas W. Chittenden X, DPHIL, Ph.D. Chief Scientific Officer NA
Dr. Cetin Savkli Ph.D. Chief AI Advisor & Member of Advisory Board NA
Mr. William Hirschman Chief Commercial Officer NA
Dr. David P. Recker FACP, FACR, M.D. Chief Medical Officer 1958

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.